ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,127.79
      1.26%
      US Tech 100
      17,438.04
      2.12%
      Dow Jones
      38,675.68
      1.18%
      Brent Oil
      82.765
      -1.03%
      Bitcoin
      62,605.74
      5.90%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Vigil Neuroscience Inc (VIGL)

      7. Vigil Neuroscience Inc (VIGL) News

      VIGL

      Vigil Neuroscience (VIGL)

      Vigil Neuroscience Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:VIGL
      DateTimeSourceHeadlineSymbolCompany
      04/17/20244:05PMGlobeNewswire Inc.Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual MeetingNASDAQ:VIGLVigil Neuroscience Inc
      03/26/20247:05AMGlobeNewswire Inc.Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:VIGLVigil Neuroscience Inc
      03/20/20247:05AMGlobeNewswire Inc.Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical OfficerNASDAQ:VIGLVigil Neuroscience Inc
      03/13/20247:05AMGlobeNewswire Inc.Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual MeetingNASDAQ:VIGLVigil Neuroscience Inc
      03/12/20247:05AMGlobeNewswire Inc.Vigil Neuroscience to Present at Stifel 2024 Virtual CNS DaysNASDAQ:VIGLVigil Neuroscience Inc
      03/06/20244:25PMGlobeNewswire Inc.Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024NASDAQ:VIGLVigil Neuroscience Inc
      03/01/20246:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIGLVigil Neuroscience Inc
      03/01/20245:50PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIGLVigil Neuroscience Inc
      02/29/20244:05PMGlobeNewswire Inc.Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024NASDAQ:VIGLVigil Neuroscience Inc
      02/14/202411:33AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VIGLVigil Neuroscience Inc
      02/07/20244:05PMGlobeNewswire Inc.Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology ConferenceNASDAQ:VIGLVigil Neuroscience Inc
      01/11/202410:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIGLVigil Neuroscience Inc
      01/03/20244:30PMGlobeNewswire Inc.Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 MilestonesNASDAQ:VIGLVigil Neuroscience Inc
      11/22/20234:05PMGlobeNewswire Inc.Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx ConferenceNASDAQ:VIGLVigil Neuroscience Inc
      11/16/20234:31PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIGLVigil Neuroscience Inc
      11/16/20234:05PMGlobeNewswire Inc.Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATENASDAQ:VIGLVigil Neuroscience Inc
      11/07/20237:30AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIGLVigil Neuroscience Inc
      11/07/20237:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIGLVigil Neuroscience Inc
      11/07/20237:05AMGlobeNewswire Inc.Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:VIGLVigil Neuroscience Inc
      10/17/20237:05AMGlobeNewswire Inc.Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s DiseaseNASDAQ:VIGLVigil Neuroscience Inc
      10/12/20234:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIGLVigil Neuroscience Inc
      10/05/20234:01PMGlobeNewswire Inc.Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro SummitNASDAQ:VIGLVigil Neuroscience Inc
      09/26/20237:05AMGlobeNewswire Inc.Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSPNASDAQ:VIGLVigil Neuroscience Inc
      09/13/20237:31AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIGLVigil Neuroscience Inc
      09/11/202312:00PMGlobeNewswire Inc.Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual MeetingNASDAQ:VIGLVigil Neuroscience Inc
      09/08/20234:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIGLVigil Neuroscience Inc
      09/08/20234:05PMGlobeNewswire Inc.Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist ProgramNASDAQ:VIGLVigil Neuroscience Inc
      09/08/20237:05AMGlobeNewswire Inc.Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare ConferenceNASDAQ:VIGLVigil Neuroscience Inc
      08/08/20237:31AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIGLVigil Neuroscience Inc
      08/08/20237:19AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIGLVigil Neuroscience Inc
       Showing the most relevant articles for your search:NASDAQ:VIGL